BioAge Labs, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation
DE
Business Address
5885 HOLLIS STREET, EMERYVILLE, CA, 94608
Mailing Address
5885 HOLLIS STREET, EMERYVILLE, CA, 94608
Phone
510-806-1445
Fiscal Year End
1231
EIN
474721157
Financial Overview
FY2025
$358.23M
Total Assets
$35.11M
Total Liabilities
$354.35M
Cash & Equivalents
$-2.24
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | April 3, 2026 | View on SEC |
| 8-K Current report of material events | March 24, 2026 | View on SEC |
| 10-K Annual financial report | March 24, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 19, 2026 | View on SEC |
| 4 Insider stock transaction report | February 19, 2026 | View on SEC |
| 4 Insider stock transaction report | February 19, 2026 | View on SEC |
| 4 Insider stock transaction report | February 19, 2026 | View on SEC |
| 4 Insider stock transaction report | February 19, 2026 | View on SEC |
Annual Reports
10-K
March 24, 2026
- Successful IPO in September 2024 raising $198 million on the Nasdaq.
- Lead drug candidate azelaprag (BGE-102) offers a convenient oral alternative to injectable weight-loss treatments.
Insider Trading
STRONG SELL
3 insiders
11 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.